Observational studyJAMA network open2026
Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.
Observational study in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The efficacy and safety of remdesivir for COVID-19 in kidney transplant (KT) recipients across evolving pandemic eras remain unclear. Objective: To compare clinical outcomes among adult KT recipients with symptomatic COVID-19 who received early remdesivir vs those who did not receive remdesivir. Design, Setting, and Participants: This retrospective cohort study emulated a target trial using observational data from 5 hospitals within the Johns Hopkins Health System. Adult KT recipients (aged ≥18 years) with a functioning allograft and symptomatic COVID-19 from March 2020 through January 2024 were eligible. Patients who received anti-SARS-CoV-2 monoclonal antibodies, nirmatrelvir-ritonavir, and/or molnupiravir were excluded. Follow-up continued for up to 1 year after COVID-19 diagnosis. Exposures: Individuals who initiated remdesivir within 7 days of diagnosis and received at least 3 consecutive days of therapy were assigned to the early remdesivir strategy, whereas those who did not receive remdesivir were assigned to the no remdesivir strategy. Main Outcomes and Measures: The primary outcome was all-cause graft loss (ACGL), a composite of graft failure and all-cause mortality. Secondary outcomes included all-cause mortality, cardiovascular events (CVEs), and long COVID. Per-protocol associations were estimated using a clone-censor-weight (CCW) approach with weighted Cox proportional hazards marginal structural regression models and robust SEs to calculate hazard ratios (HRs) and 95% CIs. Results: Among 432 KT recipients with symptomatic COVID-19 (median age, 57 years [IQR, 46-66 years]; 248 [57.4%] were male), 177 (41.0%) initiated early remdesivir and 255 (59.0%) received no remdesivir. Over 1 year of follow-up, early remdesivir initiation vs no remdesivir was associated with a lower risk of ACGL (HR, 0.53; 95% CI, 0.31-0.92) and CVEs (HR, 0.58; 95% CI, 0.35-0.98) after CCW adjustment. There was no significant association between early initiation of remdesivir and lower risk of all-cause mortality (HR, 0.51; 95% CI, 0.24-1.06) or long COVID (HR, 0.65; 95% CI, 0.21-2.05) in the weighted analysis. Conclusions and Relevance: In this target trial emulation, KT recipients with symptomatic acute COVID-19 who underwent early remdesivir treatment had reduced risk of ACGL and CVEs. These findings suggest that prompt initiation of remdesivir during COVID-19 illness may protect kidney allograft survival and cardiovascular health in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.